Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study
Mitchell E. Horwitz(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Guillermo Sanz(Instituto de Salud Carlos III), William Ying Khee Hwang(Singapore General Hospital), Olga Frankfurt, Irit Segalovich, Patrick J. Stiff(Loyola University Medical Center), David Valcárcel(Vall d'Hebron Hospital Universitari), Corey Cutler(Harvard University), Gary J. Schiller(Fred Hutch Cancer Center), Claudio G. Brunstein(Hotel Dieu Hospital), Rabi Hanna(Cleveland Clinic), Joseph P. McGuirk(University of Kansas Medical Center), Caroline A. Lindemans(University Medical Center Utrecht), Amy K. Keating(Boston Children's Hospital), Nelson Hamerschlak(Hospital Israelita Albert Einstein), Einat Galamidi-Cohen(Gamida Cell (Israel)), Andrew R. Rezvani(Stanford Blood Center), Liang Piu Koh(National University Cancer Institute, Singapore), Richard T. Maziarz(Oregon Health & Science University), Beth Blackwell(Emmes (United States)), Yasser Khaled(Methodist University Hospital), Stephen Wease(Emmes (United States)), Laurence S. Freedman(Industrial Measurement Systems (United States)), Tony Peled(Gamida Cell (Israel)), Nicole A. Karris(City of Hope)
Cited by 110
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k